DOCSLIB.ORG

Review Article Uridine Metabolism and Its Role in Glucose, Lipid, and Amino Acid Homeostasis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Review Article Uridine Metabolism and Its Role in Glucose, Lipid, and Amino Acid Homeostasis Hindawi BioMed Research International Volume 2020, Article ID 7091718, 7 pages https://doi.org/10.1155/2020/7091718 Review Article Uridine Metabolism and Its Role in Glucose, Lipid, and Amino Acid Homeostasis Yumei Zhang, Songge Guo, Chunyan Xie , and Jun Fang College of Bioscience and Biotechnology, College of Resources and Environment, Hunan Agricultural University, Changsha, 410128 Hunan, China Correspondence should be addressed to Chunyan Xie; [email protected] and Jun Fang; [email protected] Received 10 December 2019; Accepted 4 February 2020; Published 15 April 2020 Academic Editor: Flavia Prodam Copyright © 2020 Yumei Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Pyrimidine nucleoside uridine plays a critical role in maintaining cellular function and energy metabolism. In addition to its role in nucleoside synthesis, uridine and its derivatives contribute to reduction of cytotoxicity and suppression of drug-induced hepatic steatosis. Uridine is mostly present in blood and cerebrospinal fluid, where it contributes to the maintenance of basic cellular functions affected by UPase enzyme activity, feeding habits, and ATP depletion. Uridine metabolism depends on three stages: de novo synthesis, salvage synthesis pathway and catabolism, and homeostasis, which is tightly relating to glucose homeostasis and lipid and amino acid metabolism. This review is devoted to uridine metabolism and its role in glucose, lipid, and amino acid homeostasis. 1. Introduction In contrast, uridine can also regulate systemic homeosta- sis by regulating enzymes and their reaction products. Uridine, a necessary pyrimidine nucleotide for RNA synthesis, Uridine is thought to regulate the mitochondrial respiratory can be synthesized de novo in mammals [1–3]. Uridine has chain via the dihydroorotate dehydrogenase (DHODH) been widely used in reducing cytotoxicity [4] and improving enzyme, and since mitochondrial dysfunction is involved in neurophysiological functions [5, 6]. In addition, short-term many human diseases, uridine could be used as a therapeutic uridine coadministration with tamoxifen could suppress drug for mitochondrial diseases [10]. Furthermore, the accu- hepatic steatosis [2, 7–10]. In humans, uridine is present in mulation of orotate, an intermediate product in the process the blood and cerebrospinal fluid, and the content of uridine of uridine de novo synthesis, induces intracellular lipid accu- in plasma is much higher than that in other purine and mulation [14]. Accordingly, in this review, we focus on the pyrimidine nucleosides [7, 11]. Due to their inability to factors that influence uridine concentration and the role of synthesize uridine, most tissues utilize plasma uridine to uridine in the metabolism of glucose, lipid, and amino acid. maintain basic cellular functions [1, 12]. Thus, plasma uridine may be used for the synthesis of endogenous pyrim- 2. Uridine Biosynthesis and idine. The biosynthesis of uridine is regulated by the liver and Catabolism Pathway adipose tissues, and the excretion of uridine is mainly achieved via the kidneys or by pyrimidine catabolism in It is acknowledged that pyrimidine nucleotide metabolism tissues [13]. Many research studies have demonstrated that involves three pathways: de novo synthesis, salvage synthesis uridine homeostasis is affected by a variety of factors to reg- pathway, and catabolism. Within the cell, nucleotides can be ulate systemic metabolism. Factors recognized for regulating synthesized from a simple metabolite by the de novo synthe- the concentration of uridine include uridine phosphorylase sis pathway or recycled by the salvage synthesis pathway [1]. (UPase), feeding behavior, and ATP depletion. When endogenous supply is insufficient to maintain normal 2 BioMed Research International body functions, uridine is mainly exogenously supplemented phosphorylase (UPase) encoded by the UPP gene by diet to maintain normal growth and cell function [15]. (EC=2.4.2.3). UPase has two homologous forms in verte- During its catabolism, uridine is converted to β-alanine and brates: UPase1 and UPase2 [10, 11, 23]. UPase1, encoded followed by secretion to the brain and muscle tissues [1]. by the UPP1 gene, regulates uridine homeostasis and is ubiquitously expressed. Inhibition of the enzymatic activity 2.1. Uridine Biosynthesis. Uridine de novo synthesis originates of UPase1 or UPase1 gene knockout results in elevated levels from glutamine and is catalyzed by the CAD protein (which of uridine in plasma and tissues [11, 24]. UPase2 is a liver- fi encodes the rate-limiting enzymes during uridine biosynthe- speci c protein encoded by the UPP2 gene and is indispens- sis). CAD is a multidomain enzyme comprised of carbamoyl able for pyrimidine salvage reactions [2, 11]. Inhibition of phosphate synthetase (CPS II, EC=6.3.5.5), aspartic transcar- the enzymatic activity of UPase2 increases the level of bamoylase (ATCase, EC=2.1.3.2), and dihydroorotase (DHO, endogenous uridine in the liver, thereby protecting the liver EC=3.5.2.3), in which CPS II is the rate-limiting enzyme, and against drug-induced lipid accumulation [2, 25]. Next, ′ uracil is further decomposed into dihydrouracil and N-car- regulation of CPS II is mediated by uridine 5 -triphosphate β (UTP) feedback inhibition and phosphoribosyl pyrophos- bamoyl- -alanine by dihydropyrimidine dehydrogenase phate (PRPP) activation [15]. In the de novo pathway, CAD (DPD) and hydropyrimidine hydratase (also known as dihy- dropyrimidinase), which is further converted to β-alanine by catalyzed glutamine produces the intermediate metabolites β β carbamoyl phosphate, carbamoyl aspartate, and dihydrooro- -ureidopropionase (EC=3.5.1.6) [1, 10]. -Alanine is tate (Figure 1). excreted or enters other tissues, such as the brain and muscle. The fourth step in pyrimidine biosynthesis is catalyzed by DHODH, to form an important intermediate, orotate. The accumulation of orotate may induce intracellular lipid 3. The Regulation Mechanism of the accumulation [10]. DHODH is a mitochondrial, respiratory Uridine Concentration chain-coupled enzyme on the outer surface of the mitochon- drial inner membrane, which links pyrimidine biosynthesis The plasma uridine concentration in mammals is between 3 to mitochondrial energy metabolism [10, 15]. Then, orotate and 8 μM, which is higher than other pyrimidine nucleotides is converted to orotidine monophosphate (OMP) and and bases [1, 26]. Most tissues cannot synthesize uridine; uridine monophosphate (UMP) by orotate phosphoribosyl- thus, use plasma as a uridine source [7, 11]. Plasma uridine transferase and orotidine 5′-phosphate decarboxylase, concentration is tightly controlled by a variety of factors in respectively. Then, UMP is dephosphorylated to uridine by both humans and rodents [1, 27]. However, there is no nucleotidase or formed from cytidine by cytidine deaminase review of factors that regulate the concentration of uridine (EC=3.5.4.5) [1, 10, 12]. at present. Therefore, we next focus on factors that regulate A recent study has shown that resting/low proliferating the concentration of uridine and its mechanisms. cells rely mainly on the nucleotide salvage pathway to synthe- size RNA [16]. Also, uridine can be obtained from UTP and ′ 3.1. Feeding Behavior Regulates the Plasma Concentration of cytosine 5 -triphosphate (CTP) via the pyrimidine salvage Uridine. A series of recent studies indicate that the dynamic pathway. UTP is also involved in glycogen synthesis, protein regulation of plasma uridine is related to feeding behavior glycosylation, and membrane phospholipid biosynthesis [11, 23]. As the main organ in uridine biosynthesis, the liver – [17 19]. In the pyrimidine nucleotide salvage synthesis path- maintains uridine homeostasis by regulating glucose metabo- way, uridine-cytidine kinase 2 (UCK2) acts as a phosphory- lism during different feeding states [12, 27]. In the fed period, lase responsible for phosphorylating pyrimidine nucleotides uridine synthesis occurs mainly in the liver tissue. However, in (uridine and cytidine) to the corresponding monophosphates the fasted period, uridine synthesis depends on adipocytes, as [15]. Nucleoside monophosphate kinase further phosphory- the liver focuses on glucose production [12]. Experiments to ′ lates UMP and CMP to produce uridine 5 -diphosphate study how fasting and refeeding can cause changes in plasma (UDP) and cytosine 5′-diphosphate (CDP). UDP and CDP uridine levels were performed in C57BL/6 mice, Sprague- are further phosphorylated by the nucleoside diphosphate Dawley rats, and healthy women. In the fasted state, adipose kinase to produce UTP and CTP. Subsequently, UTP and tissue elevated the plasma concentration of uridine via uridine CTP are used only for gene duplication. During nucleic acid biosynthesis, while plasma uridine levels decreased rapidly catabolism, some nucleoside monophosphates (NMPs) are after refeeding [27]. The reduction is caused by a decrease in released and reused in the salvage synthesis pathway by uridine synthesis in adipocytes and an increase in uridine UCK2 [20]. In mammals, UCK2 is allosterically activated by clearance in bile [27–29]. ATP to synthesize the pyrimidine nucleotides required for Uridine can be catalyzed in vivo into uracil by uridine cellular metabolism. Nucleotide production is controlled by phosphorylase. It is hypothesized that
Load more

Recommended publications
  • The Effect of an Oral Or Intravenous Nucleotide-Free Diet on Selected Enzyme Activities in Purine Metabolism in Rats
    RICE UNIVERSITY THE EFFECT OF AN ORAL OR INTRAVENOUS NUCLEOTIDE-FREE DIET ON SELECTED ENZYME ACTIVITIES IN PURINE METABOLISM IN RATS. by SANDRA LYNN SNYDER A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE MASTER OF ARTS APPROVED, THESIS COMMITTEE: .T Dr. Frederi Associate Professor of B Chemistry Dr. Susan M. B^fget Assistant Professor of Biochemistry Dr. George J. Æchfoépfer Professor of Biochemistry and Chemistry Dr. George'N. Bennett Assistant Professor of Biochemistry Dr. Roger L. Storck Professor of Biology HOUSTON, TEXAS MARCH, 1982 ABSTRACT THE EFFECT OF AN ORAL OR INTRAVENOUS NUCLEOTIDE-FREE DIET ON SELECTED ENZYME ACTIVITIES IN PURINE METABOLISM IN RATS SANDRA LYNN SNYDER Interrelationships between purine metabolism and immunity, cancer, and the diet have been considered. In studying trends of metabolic changes which occur in response to changes in the purine content of the diet, it has been hypothesized that when purines are lacking from the diet, there is a general shift from a catabolic to an anabolic state. In the present investigation, the activities of selected enzymes on purine metabolism in rats were studied with respect to an oral or intravenous nucleotide-free diet compared to the activities in rats fed normal chow. The intravenous nucleotide-free diet caused a decrease in purine nucleoside phosphorylase activity, an increase in adenine phosphoribosyl transferase, and no change in the activity of hypoxanthine-guanine phosphoribosyl transferase, with respect to a normal control diet. The orally fed nucleotide-free diet caused a decrease in the activity of purine nucleoside phosphorylase and xanthine oxidase and increase in pancreatic ribonucléase and no change in adenine phosphoribosyl transferase or hyphoxanthine-guanine phosphoribosyl transferase, with respect to a normal control diet.
    [Show full text]
  • Is Human Hibernation Possible?
    ANRV334-ME59-12 ARI 16 December 2007 14:50 Is Human Hibernation Possible? Cheng Chi Lee Department of Biochemistry and Molecular Biology, University of Texas Health Science Center, Houston, Texas 77030; email: [email protected] Annu. Rev. Med. 2008. 59:177–86 Key Words The Annual Review of Medicine is online at hypothermia, 5-AMP, torpor, hypometabolism http://med.annualreviews.org This article’s doi: Abstract 10.1146/annurev.med.59.061506.110403 The induction of hypometabolism in cells and organs to reduce is- Copyright c 2008 by Annual Reviews. chemia damage holds enormous clinical promise in diverse fields, in- All rights reserved cluding treatment of stroke and heart attack. However, the thought 0066-4219/08/0218-0177$20.00 that humans can undergo a severe hypometabolic state analogous to hibernation borders on science fiction. Some mammals can enter a severe hypothermic state during hibernation in which metabolic activity is extremely low, and yet full viability is restored when the animal arouses from such a state. To date, the underlying mecha- nism for hibernation or similar behaviors remains an enigma. The beneficial effect of hypothermia, which reduces cellular metabolic demands, has many well-established clinical applications. However, severe hypothermia induced by clinical drugs is extremely difficult and is associated with dramatically increased rates of cardiac arrest for nonhibernators. The recent discovery of a biomolecule, 5-AMP, which allows nonhibernating mammals to rapidly and safely enter severe hypothermia could remove this impediment and enable the wide adoption of hypothermia as a routine clinical tool. 177 ANRV334-ME59-12 ARI 16 December 2007 14:50 INTRODUCTION ing mammals.
    [Show full text]
  • The Regulation of Carbamoyl Phosphate Synthetase-Aspartate Transcarbamoylase-Dihydroorotase (Cad) by Phosphorylation and Protein-Protein Interactions
    THE REGULATION OF CARBAMOYL PHOSPHATE SYNTHETASE-ASPARTATE TRANSCARBAMOYLASE-DIHYDROOROTASE (CAD) BY PHOSPHORYLATION AND PROTEIN-PROTEIN INTERACTIONS Eric M. Wauson A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Pharmacology. Chapel Hill 2007 Approved by: Lee M. Graves, Ph.D. T. Kendall Harden, Ph.D. Gary L. Johnson, Ph.D. Aziz Sancar M.D., Ph.D. Beverly S. Mitchell, M.D. 2007 Eric M. Wauson ALL RIGHTS RESERVED ii ABSTRACT Eric M. Wauson: The Regulation of Carbamoyl Phosphate Synthetase-Aspartate Transcarbamoylase-Dihydroorotase (CAD) by Phosphorylation and Protein-Protein Interactions (Under the direction of Lee M. Graves, Ph.D.) Pyrimidines have many important roles in cellular physiology, as they are used in the formation of DNA, RNA, phospholipids, and pyrimidine sugars. The first rate- limiting step in the de novo pyrimidine synthesis pathway is catalyzed by the carbamoyl phosphate synthetase II (CPSase II) part of the multienzymatic complex Carbamoyl phosphate synthetase, Aspartate transcarbamoylase, Dihydroorotase (CAD). CAD gene induction is highly correlated to cell proliferation. Additionally, CAD is allosterically inhibited or activated by uridine triphosphate (UTP) or phosphoribosyl pyrophosphate (PRPP), respectively. The phosphorylation of CAD by PKA and ERK has been reported to modulate the response of CAD to allosteric modulators. While there has been much speculation on the identity of CAD phosphorylation sites, no definitive identification of in vivo CAD phosphorylation sites has been performed. Therefore, we sought to determine the specific CAD residues phosphorylated by ERK and PKA in intact cells.
    [Show full text]
  • Proteomic Analysis of the Rad18 Interaction Network in DT40 – a Chicken B Cell Line
    Proteomic analysis of the Rad18 interaction network in DT40 – a chicken B cell line Thesis submitted for the degree of Doctor of Natural Sciences at the Faculty of Biology, Ludwig-Maximilians-University Munich 15th January, 2009 Submitted by Sushmita Gowri Sreekumar Chennai, India Completed at the Helmholtz Zentrum München German Research Center for Environmental Health Institute of Clinical Molecular Biology and Tumor Genetics, Munich Examiners: PD Dr. Berit Jungnickel Prof. Heinrich Leonhardt Prof. Friederike Eckardt-Schupp Prof. Harry MacWilliams Date of Examination: 16th June 2009 To my Parents, Sister, Brother & Rajesh Table of Contents 1. SUMMARY ........................................................................................................................ 1 2. INTRODUCTION ............................................................................................................. 2 2.1. MECHANISMS OF DNA REPAIR ......................................................................................... 3 2.2. ADAPTIVE GENETIC ALTERATIONS – AN ADVANTAGE ....................................................... 5 2.3. THE PRIMARY IG DIVERSIFICATION DURING EARLY B CELL DEVELOPMENT ...................... 6 2.4. THE SECONDARY IG DIVERSIFICATION PROCESSES IN THE GERMINAL CENTER .................. 7 2.4.1. Processing of AID induced DNA lesions during adaptive immunity .................. 9 2.5. TARGETING OF SOMATIC HYPERMUTATION TO THE IG LOCI ............................................ 10 2.6. ROLE OF THE RAD6 PATHWAY IN IG DIVERSIFICATION
    [Show full text]
  • Enhancing Nucleotide Metabolism Protects Against Mitochondrial Dysfunction and Neurodegeneration in a PINK1 Model of Parkinson’S Disease
    ARTICLES Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson's disease Roberta Tufi1, Sonia Gandhi2, Inês P. de Castro1, Susann Lehmann1, Plamena R. Angelova2, David Dinsdale1, Emma Deas2, Hélène Plun-Favreau2, Pierluigi Nicotera3, Andrey Y. Abramov2, Anne E. Willis1, Giovanna R. Mallucci1, Samantha H. Y. Loh1,4 and L. Miguel Martins1,4 Mutations in PINK1 cause early-onset Parkinson's disease (PD). Studies in Drosophila melanogaster have highlighted mitochondrial dysfunction on loss of Pink1 as a central mechanism of PD pathogenesis. Here we show that global analysis of transcriptional changes in Drosophila pink1 mutants reveals an upregulation of genes involved in nucleotide metabolism, critical for neuronal mitochondrial DNA synthesis. These key transcriptional changes were also detected in brains of PD patients harbouring PINK1 mutations. We demonstrate that genetic enhancement of the nucleotide salvage pathway in neurons of pink1 mutant flies rescues mitochondrial impairment. In addition, pharmacological approaches enhancing nucleotide pools reduce mitochondrial dysfunction caused by Pink1 deficiency. We conclude that loss of Pink1 evokes the activation of a previously unidentified metabolic reprogramming pathway to increase nucleotide pools and promote mitochondrial biogenesis. We propose that targeting strategies enhancing nucleotide synthesis pathways may reverse mitochondrial dysfunction and rescue neurodegeneration in PD and, potentially, other diseases linked to mitochondrial impairment. The role of mitochondrial impairment in PD has long been debated. By combining transcriptional and metabolic profiling, we have Recently, the identification of causative mutations in PINK1, a gene uncovered significant alterations in the nucleotide metabolism encoding a mitochondrial kinase in PD patients has renewed interest in networks of pink1 mutant flies.
    [Show full text]
  • Navigating Metabolism
    This is a free sample of content from Navigating Metabolism. Click here for more information on how to buy the book. Index Page references followed by b denote boxes; those followed by f denote figures; those followed by t denote tables. A Acyl-CoA synthetase, 110 Acyl transacylase, 107, 109f ACC (acetyl-CoA carboxylase), 105, 107, Adenine, 148, 149f, 155, 157f. 109f, 113, 115, 117, 173 See also Purines Acetate, 182, 193 Adenine nucleotide transporter (ANT), 38, Acetoacetate, 116b, 117b 47f, 53, 56–57 Acetone, 116b, 117b Adenosine, 142, 143f, 164–165, 164f Acetylation, 181–183, 184f Adenosine deaminase, 165 acetyl-CoA and, 9, 10f, 181–183, 184f Adenosine phosphoribosyltransferase (APRT), of lysine residues, 2, 183 155, 157f Acetyl-CoA, 2 Adenylate kinase, 16, 32, 112, 152, 154f allosteric regulation of pyruvate Adenylosuccinate, 152, 154f–155f carboxylase, 93 ADP from citrate, 43, 53, 56f, 59, 60f, 71, 72f, adenine nucleotide transporter (ANT), 38, 47f, 107, 108f 53, 56–57 citrate transporter and, 53–54, 56f adenylate kinase reaction, 16, 32, 112 entry into TCA cycle, 41, 42f energy charge, 18 in fatty acid synthesis, 107–110, 108f–109f P2 purinoreceptor activation, generation of, 39, 41, 42f, 43, 45, 45f, 164, 164f 53–54, 56f, 59 Aerobic glycolysis, 34–35, 190, 220 metabolic functions, 9, 10f, 53 Aging posttranslational modifications and, free radical theory of, 83b 181–183, 184f metabolism and, 212 Acetyl-CoA carboxylase (ACC), 105, 107, AKT, 120, 168f, 169–170, 199 109f, 113, 115, 117, 173 Alanine Acetylserotonin O-methyltransferase, β-alanine, 161–162, 163f 139, 140f conversion to pyruvate, 93 Aconitase, 60, 70 generation of, 130, 132f Activation energy, 13, 13f, 18 from pyruvate, 26 Active site, 20 urea cycle and, 134 Acyclglycerophosphate acyltransferase, 110, 111f Alanine aminotransferase, 134 ACYL (ATP-citrate lyase), 53, 56f, 59, 71, Albinism, 41 72f, 107, 108f, 182, 192 Alcohol dehydrogenase, 31f 233 © 2015 by Cold Spring Harbor Laboratory Press.
    [Show full text]
  • Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS
    Protein identities in EVs isolated from U87-MG GBM cells as determined by NG LC-MS/MS. No. Accession Description Σ Coverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs # AAs MW [kDa] calc. pI 1 A8MS94 Putative golgin subfamily A member 2-like protein 5 OS=Homo sapiens PE=5 SV=2 - [GG2L5_HUMAN] 100 1 1 7 88 110 12,03704523 5,681152344 2 P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - [MYL6_HUMAN] 100 3 5 17 173 151 16,91913397 4,652832031 3 Q6ZYL4 General transcription factor IIH subunit 5 OS=Homo sapiens GN=GTF2H5 PE=1 SV=1 - [TF2H5_HUMAN] 98,59 1 1 4 13 71 8,048185945 4,652832031 4 P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 97,6 5 5 35 917 375 41,70973209 5,478027344 5 P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 - [RINI_HUMAN] 96,75 1 12 37 173 461 49,94108966 4,817871094 6 P09382 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 - [LEG1_HUMAN] 96,3 1 7 14 283 135 14,70620005 5,503417969 7 P60174 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - [TPIS_HUMAN] 95,1 3 16 25 375 286 30,77169764 5,922363281 8 P04406 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - [G3P_HUMAN] 94,63 2 13 31 509 335 36,03039959 8,455566406 9 Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 - [TEBP_HUMAN] 93,13 1 5 12 74 160 18,68541938 4,538574219 10 P09417 Dihydropteridine reductase OS=Homo sapiens GN=QDPR PE=1 SV=2 - [DHPR_HUMAN] 93,03 1 1 17 69 244 25,77302971 7,371582031 11 P01911 HLA class II histocompatibility antigen,
    [Show full text]
  • Human Hypoxanthine (Guanine) Phosphoribosyltransferase: An
    Proc. NatL Acad. Sci. USA Vol. 80, pp. 870-873, Febriary 1983 Medical Sciences Human hypoxanthine (guanine) phosphoribosyltransferase: An amino acid substitution in a mutant form of the enzyme isolated from a patient with gout (reverse-phase HPLC/peptide mapping/mutant enzyme) JAMES M. WILSON*t, GEORGE E. TARRt, AND WILLIAM N. KELLEY*t Departments of *Internal Medicine and tBiological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109 Communicated by James B. Wyngaarden, November 3, 1982 ABSTRACT We have investigated the molecular basis for a tration ofenzyme protein. in both erythrocytes (3) and lympho- deficiency ofthe enzyme hypoxanthine (guanine) phosphoribosyl- blasts (4); (ii) a normal Vm., a normal Km for 5-phosphoribosyl- transferase (HPRT; IMP:pyrophosphate-phosphoribosyltransfer- 1-pyrophosphate, and a 5-fold increased Km for hypoxanthine ase, EC 2.4.2.8) in a patient with a severe form of gout. We re-. (unpublished data); (iii) a normal isoelectric point (3, 4) and ported in previous studies the isolation of a unique structural migration during nondenaturing polyacrylamide gel electro- variant of HPRT from this patient's erythrocytes and cultured phoresis (4); and (iv) -an apparently smaller subunit molecular lymphoblasts. This enzyme variant, which is called HPRTOnd0., weight as evidenced by an increased mobility during Na- is characterized by a decreased concentration of HPRT protein DodSO4/polyacrylamide gel electrophoresis (3, 4). in erythrocytes and lymphoblasts, a normal Vm.., a 5-fold in- Our study ofthe tryptic peptides and amino acid composition creased Km for hypoxanthine, a normal isoelectric point, and an of apparently smaller subunit molecular weight. Comparative pep- HPRTLondon revealed a single amino acid substitution (Ser tide mapping-experiments revealed a single abnormal tryptic pep- Leu) at position 109.
    [Show full text]
  • 1 Targeting Subtype-Specific Metabolic Preferences in Nucleotide
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.19.049577; this version posted May 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Targeting subtype-specific metabolic preferences in nucleotide biosynthesis inhibits tumor growth in a breast cancer model Martin P. Ogrodzinski1,2, Shao Thing Teoh1, and Sophia Y. Lunt1,3* 1Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA 2Department of Physiology, Michigan State University, East Lansing, MI, USA 3Department of Chemical Engineering and Materials Science, Michigan State University, East Lansing, MI, USA *Correspondence: Sophia Y. Lunt, Ph.D. Biochemistry Building 603 Wilson Rd Room 522A Michigan State University East Lansing, MI 48824, USA Phone: 517-432-4886 Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.04.19.049577; this version posted May 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. ABSTRACT Investigating metabolic rewiring in cancer can lead to the discovery of new treatment strategies for breast cancer subtypes that currently lack targeted therapies. Using MMTV- Myc driven tumors to model breast cancer heterogeneity, we investigated metabolic differences between two histological subtypes, the epithelial-mesenchymal transition (EMT) and the papillary subtypes, using a combination of genomic and metabolomic techniques. We identified differences in nucleotide metabolism between EMT and papillary subtypes: EMT tumors preferentially use the nucleotide salvage pathway, while papillary tumors prefer de novo nucleotide biosynthesis.
    [Show full text]
  • Studies on the Mechanism of Action of 6-Mercaptopurine in Sensitive and Resistant L1210 Leukemia in Vitro*
    Studies on the Mechanism of Action of 6-Mercaptopurine in Sensitive and Resistant L1210 Leukemia in Vitro* JACKD. DAVIDSON (Clinical Pharmacology and Experimental Tlierapeutics Service, National Cancer Institute, Betliesda, Md.) SUMMARY A study was made of the effects of 6-mercaptopurine (6-MP) upon nucleic acid metabolism in L1210 leukemia cells in vitro. Pharmacological concentrations of 6-MP inhibited the incorporation of both hypoxanthine and glycine into adenine nucleo- tides. Higher concentrations of 6-MP inhibited the incorporation of hypoxanthine into both adenine and guanine nucleotides. In a subline of L1210 which is resistant to 6-MP there was much less utilization of hypoxanthine than in the sensitive line, and incorporation into both adenine and guanine moieties was strongly inhibited by 6-MP. On the contrary, utilization of glycine for nucleotide purine synthesis was unaffected by 6-MP. These findings support the hypothesis that in L1210 leukemia 6-MP is metabolized to its ribotide, and this produces a metabolic block in the conversion of inosinic acid to adenylic acid. They further indicate that, in the L1210 cells resistant to 6-MP, there is a very limited capacity to convert 6-MP and hypoxanthine to ribotides. This leads to competition between 6-MP and hypoxanthine and to formation of insufficient 6-MP ribotide to cause the critical block. Although 6-mercaptopurine (6-MP) has been purines isolated from L1210 ascites leukemia cells studied with respect to its antitumor activity since have been studied. The results obtained suggest 1952, there is still relatively little information re that the primary antimetabolic activity of 6-MP garding the mechanism of its action.
    [Show full text]
  • When the Reaction Is
    Table S3. iJL1678-ME model modification (blocked reactions) Iter. Cat. ID Name Formula Subsystem Comments (When the reaction is turned on) 1 bp2 EDD 6-phosphogluconate dehydratase 6pgc_c⇌2ddg6p_c + h2o_c Pentose Phosphate Pathway Create a major effect of steep acetate overflow elevation in high growth. Comparing to the main glycolytic pathway, it is metabolicly less efficient but proteomicly more efficient. bp1 ICL Isocitrate lyase icit_c→glx_c + succ_c Anaplerotic Reactions Bypass for the main TCA cycle pathways from turning isocitrate to succinate, when ICL is turned on, Isocitrate dehydrogenase(ICDHyr), 2-Oxogluterate dehydrogenase(AKGDH) and Succinyl-CoA synthetase (ATP-forming,SUCOAS) would reduce. Ref. (1) and (2) shows that this reaction is off in higher growth. Ref. (3) shows that this reaction is converging to being off when the dynamic of respiration using enzyme kinetics is simulated. 2 bp1 ABTA 4-aminobutyrate transaminase 4abut_c + akg_c⇌glu__L_c + sucsal_c Arginine and Proline Metabolism Another backup pathway of succinate production, from 2-Oxoglutarate (akg). Respiration would be induced when it is on, since the flux through ETC(CYTBO3_4pp and ATPS4rpp) would increase. As it requires the co-factor pyridoxal 5'-phosphate(2−) to get catalyzed(4), indicating that this reaction is regulated by the flux of other reactions(pyridoxal 5'- phosphate(2-) production, etc.). 3 GLYAT Glycine C-acetyltransferase accoa_c + gly_c⇌2aobut_c + coa_c Glycine and Serine Metabolism A reaction that back up for the respiration. Reactions fluxes in TCA cycle would drop when this reaction is turned on. It also requires pyridoxal 5'-phosphate(2−) for the regulation. 4 NADTRHD NAD transhydrogenase nad_c + nadph_c⇌nadh_c + nadp_c Oxidative Phosphorylation A reaction that would make the transition between NAD and NADP metabolically more efficient.
    [Show full text]
  • Central Nervous System Dysfunction and Erythrocyte Guanosine Triphosphate Depletion in Purine Nucleoside Phosphorylase Deficiency
    Arch Dis Child: first published as 10.1136/adc.62.4.385 on 1 April 1987. Downloaded from Archives of Disease in Childhood, 1987, 62, 385-391 Central nervous system dysfunction and erythrocyte guanosine triphosphate depletion in purine nucleoside phosphorylase deficiency H A SIMMONDS, L D FAIRBANKS, G S MORRIS, G MORGAN, A R WATSON, P TIMMS, AND B SINGH Purine Laboratory, Guy's Hospital, London, Department of Immunology, Institute of Child Health, London, Department of Paediatrics, City Hospital, Nottingham, Department of Paediatrics and Chemical Pathology, National Guard King Khalid Hospital, Jeddah, Saudi Arabia SUMMARY Developmental retardation was a prominent clinical feature in six infants from three kindreds deficient in the enzyme purine nucleoside phosphorylase (PNP) and was present before development of T cell immunodeficiency. Guanosine triphosphate (GTP) depletion was noted in the erythrocytes of all surviving homozygotes and was of equivalent magnitude to that found in the Lesch-Nyhan syndrome (complete hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency). The similarity between the neurological complications in both disorders that the two major clinical consequences of complete PNP deficiency have differing indicates copyright. aetiologies: (1) neurological effects resulting from deficiency of the PNP enzyme products, which are the substrates for HGPRT, leading to functional deficiency of this enzyme. (2) immunodeficiency caused by accumulation of the PNP enzyme substrates, one of which, deoxyguanosine, is toxic to T cells. These studies show the need to consider PNP deficiency (suggested by the finding of hypouricaemia) in patients with neurological dysfunction, as well as in T cell immunodeficiency. http://adc.bmj.com/ They suggest an important role for GTP in normal central nervous system function.
    [Show full text]